ClinicalTrials.gg
CompletedNCT01050530Updated Mar 4, 2014Results posted

A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema

A Phase 3 interventional study of OPC-41061 and Placebo in Cirrhosis, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 8 sites in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-03-04.

Primary conditionFibrosis(the registry's first term)UnverifiedIs this wrong?Fibrosis is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

OPC-41061 at 7.5 mg/day or placebo will be orally administered once daily for 7 days to cirrhosis patients with ascites despite having received treatment with conventional diuretics and the change in body weight from baseline at the time of the final administration will be compared between the two groups.

02

Conditions studied

  • Cirrhosis

Browse trials for

Keywords

  • Cirrhosis
  • ascites
  • Tolvaptan
  • OPC-41061
03

In context

Fibrosis Unverified

1,271 studies on the registry are indexed under Fibrosis; 277 are open to participants now.

This study's enrollment of 162 is above the median of 63 across 841 interventional studies indexed under Fibrosis.

Browse Fibrosis studies →

Lead sponsor

Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.

Compared within Fibrosis, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients judged as having cirrhosis based on previous imaging diagnosis

    • Definition of cirrhosis includes patients with collateral circulation due to chronic hepatic impairment
  • Patients with ascites in whom the dose of existing diuretics cannot be increased due to risk of adverse drug reactions such as electrolyte abnormalities, or in whom sufficient therapeutic effect cannot be obtained with existing diuretics
  • Patients who have been receiving oral combination therapy with a loop diuretic and an anti-aldosterone agent from at least 7 days prior to receipt of , with a dose combination of either loop diuretic equivalent to furosemide 40 mg/day or higher plus spironolactone 25 mg/day or higher, or loop diuretic equivalent to furosemide 20 mg/day or higher plus spironolactone 50 mg/day or higher
  • Patients who are hospitalized or who can be hospitalized for the trial
  • Patients capable of giving informed consent
  • Patients who, together with their partner, agree to use an appropriate method of until 4 weeks after the final trial drug administration

Exclusion criteria

Exclusion Criteria:

  • Patients with any of the following complications or symptoms:
  • Hepatic encephalopathy (hepatic coma of grade 2 or higher)
  • Hepatocellular carcinoma with imaging-diagnosed vascular infiltration into trunk or primary branch of portal vein, inferior vena cava, or trunk of hepatic vein
  • Endoscopic findings from screening examination or from within 30 days prior to screening examination indicating the need for new therapy for esophageal or gastric varices during the trial period
  • Repeated hemorrhoidal bleeding due to rectal varicose veins within 30 days prior to
  • Heart failure ( Class III or IV)
  • Anuria
  • Impaired urination due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause
  • Patients with a history of any of the following disorders:
  • Cerebrovascular disorder within 30 days prior to informed consent
  • or idiosyncratic reaction to benzazepine derivatives (such as mozavaptan hydrochloride or benazepril hydrochloride)
  • Morbidly obese patients with a (BMI: body weight (kg)/height (m)2) exceeding 35
  • Patients with sitting systolic blood pressure lower than 90 mmHg
  • Patients with any of following abnormal clinical laboratory values at time of the screening examination: lower than 8.0 g/dL, total higher than 4.0 mg/dL, serum creatinine higher than 2.0 mg/dL, serum sodium higher than 147 mEq/L, or serum potassium higher than 5.5 mEq/L
  • Patients who are unable to take oral medication
  • Female patients who are pregnant, possibly pregnant, or breast-feeding, or who are planning to become pregnant
  • Patients who have used albumin preparations (therapeutic agents for hypoalbuminemia) or blood products containing albumin from within 7 days prior to informed consent
  • Patients who received any drug other than OPC-41061 within 30 days prior to informed consent
  • Patients who have previously received OPC-41061
  • Any patient who, in the opinion of the principle investigator or subinvestigator, is inappropriate for participation in the trial
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    OPC-41061

    Drug: OPC-41061

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days

  • DrugPlacebo

    Once-daily oral administration of placebo after breakfast for 7 days

06

What researchers measure

Primary outcomes

  1. Body weight

    Change in body weight from baseline after 7-day repeated oral administration of OPC

    Time frame: Baseline, Day 7 or at the discontinued of treatment

Secondary outcomes

  1. Ascites Volume

    Change in ascites volume from baseline as measured by CT at end of treatment

    Time frame: Baseline, Day 7 or at the discontinued of treatment

07

Results

Posted Jan 31, 2014

Participant flow

Participant flow — Overall Study
MilestoneOPC-41061Placebo
Started8280
Completed7470
Not completed810
Withdrew: Adverse event63
Withdrew: Lack of efficacy14
Withdrew: Withdrawal by subject03
Withdrew: Protocol violation10

Outcome measures

PrimaryBody weight

Change in body weight from baseline after 7-day repeated oral administration of OPC

Time frame:
Baseline, Day 7 or at the discontinued of treatment
Reported as:
Mean · Kg
Body weight
KgOPC-41061Placebo
Body weight-1.95 ± 1.77-0.44 ± 1.93
Statistical analysis
  • OPC-41061 vs Placebo · t-test, 2 sided · p = <0.0001 · Mean difference (final values): -1.51 · 95% CI -2.08 to -0.93
SecondaryAscites Volume

Change in ascites volume from baseline as measured by CT at end of treatment

Time frame:
Baseline, Day 7 or at the discontinued of treatment
Reported as:
Mean · mL
Ascites Volume
mLOPC-41061Placebo
Ascites Volume-492.4 ± 760.3-191.8 ± 690.8
Statistical analysis
  • OPC-41061 vs Placebo · t-test, 2 sided · p = 0.0093 · Mean difference (final values): -300.7 · 95% CI -526.2 to -75.1

Adverse events

Collected over 7 days. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OPC-41061—7/82 (8.5%)36/82 (43.9%)
Placebo—10/80 (12.5%)26/80 (32.5%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventOPC-41061Placebo
Hepatic EncephalopathyNervous system disorders1/823/80
Femoral Neck FractureInjury, poisoning and procedural complications0/822/80
Iron Deficiency AnaemiaBlood and lymphatic system disorders0/821/80
Oesophageal Varices HaemorrhageGastrointestinal disorders0/821/80
PneumoniaInfections and infestations0/821/80
Coma HepaticNervous system disorders0/821/80
Renal FailureRenal and urinary disorders0/821/80
Renal ImpairmentRenal and urinary disorders1/821/80
Disseminated Intravascular CoagulationBlood and lymphatic system disorders1/820/80
Hepatic CirrhosisHepatobiliary disorders1/820/80
Most frequent other events
Showing 10 of 14
Most frequent other events
EventOPC-41061Placebo
ThirstGeneral disorders11/821/80
ConstipationGastrointestinal disorders6/826/80
PyrexiaGeneral disorders4/826/80
DiarrhoeaGastrointestinal disorders6/824/80
PollakiuriaRenal and urinary disorders6/820/80
Renal ImpairmentRenal and urinary disorders5/825/80
Blood Urea IncreasedInvestigations1/824/80
VomitingGastrointestinal disorders4/822/80
InsomniaPsychiatric disorders4/820/80
HyperammonaemiaInvestigations2/823/80

Baseline characteristics

Age, Continuous
Age, Continuous(years)OPC-41061PlaceboTotal
Mean66.3 ± 9.466.4 ± 8.766.4 ± 9.1
Age, Categorical
Age, Categorical(Participants)OPC-41061PlaceboTotal
<=18 years000
Between 18 and 65 years322961
>=65 years5051101
Sex: Female, Male
Sex: Female, Male(Participants)OPC-41061PlaceboTotal
Female303161
Male5249101
Region of Enrollment
Region of Enrollment(participants)OPC-41061PlaceboTotal
Japan8280162
08

Study locations

8 sites
  • Chubu Region, Japan
  • Chugoku Region, Japan
  • Hokkaido Region, Japan
  • Kanto Region, Japan
  • Kinki Region, Japan
  • Kyushu Region, Japan
  • Shikoku Region, Japan
  • Tohoku Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2010
First posted
Jan 15, 2010
Start
Dec 2009
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results first posted
Jan 31, 2014
Last update
Mar 4, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01050530
Responsible party
Sponsor
First posted
Jan 15, 2010
Start date
Dec 2009
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Jan 31, 2014
Last update
Mar 4, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion